Study results have validated that five routinely measured clinical values reliably identified patients with type 2 diabetes who had significantly different A1c responses to two important classes of ...

In September, Indian drug manufacturer Alembic received a tentative nod from the US Food and Drug Administration (FDA) to manufacture generic alogliptin as well as the alogliptin/metformin fixed-drug ...

A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Most adults with type 2 diabetes receiving an ...

A new study in Current Pharmaceutical Analysis highlights the potential of essential oil compounds derived from the Plectranthus neochilus plant as promising antidiabetic agents (1 ✔ ✔Trusted Source ...

person doing fingertip test for blood glucose, with vacuum tube for blood testing of test blood with covid-19 label Investigators aimed to determine the association of pre-existing DPP-4is use with ...

In a recent large-scale retrospective cohort study published in the journal Primary Care Diabetes, researchers used a comprehensive (n = 10,465) database-derived dataset to evaluate the adherence and ...

Initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2is) was associated with a 34% lower rate of recurrent gout flare compared with initiation of dipeptidyl peptidase 4 inhibitors (DPP-4is).

In the report, published Tuesday, Consumer Reports analyzed 23 protein powders and shakes — a range of dairy, beef and ...

DPP-4 exists as a membrane-bound form, widely expressed and enzymatically active on numerous cell types and different vascular beds... ...as well as a soluble form ...

LONDON (Reuters) - Bristol-Myers Squibb and AstraZeneca's experimental diabetes drug Onglyza significantly improves blood sugar control when added to older medicines, researchers said on Monday. Sign ...